Pfizer Earnings Preview: Key Factors to Watch Ahead of Q3 Report
Pfizer prepares to release third-quarter earnings against a backdrop of declining year-over-year projections. Analysts anticipate $0.63 EPS on $16.51 billion revenue, down from $1.06 EPS and $17.7 billion in Q3 2022. The pharmaceutical giant maintains an impressive earnings beat record, surpassing estimates in 15 of the last 16 quarters.
Pipeline developments take center stage, with Elrexfio for multiple myeloma and Sigvotatug Vedotin for NSCLC positioned as potential revenue drivers. Phase III vaccine programs for C. difficile and Lyme disease may draw investor attention as near-term catalysts.
Legal complexities emerge as Pfizer contests Novo Nordisk's acquisition of Metsera through litigation. Market participants will scrutinize management commentary on this dispute alongside updates regarding US policy impacts, given America's disproportionate contribution to total sales.